At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 91 enrolled
Drug / intervention
AVTX-002 +1 moredrug
Likely dose
AVTX-002 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma
In Brief
A Phase 2 clinical trial evaluating AVTX-002 and Placebo for Non-Eosinophilic Asthma. Completed, enrolled 91 participants across 24 sites.
Detailed Summary
The primary objective of this study is to evaluate the efficacy of AVTX-002 compared with placebo in patients with poorly controlled non-eosinophilic asthma (NEA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Eosinophilic Asthma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
Enrollment StartFeb 2022
First PostedMar 2022
Primary CompletionMay 2023
TodayJul 2026
First PostedMar 21, 2022
Enrollment StartFeb 24, 2022
Primary CompletionMay 11, 2023
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 4.3 years ago
Interventions
AVTX-002drug
Dose of 600 mg administered subcutaneously three times during the study.
Placebodrug
Placebo sourced as normal saline administered subcutaneously three times during the study.